Brief: Swedish drug maker ISR to launch phase IIa study
Jan 12 (Reuters) - Isr Immune System Regulation Holding Ab
(Publ) ISR.ST :
* SWEDISH REGULATOR APPROVES Q1 LAUNCH OF PHASE IIA STUDY
Source text for Eikon: urn:newsml:reuters.com:*:nWkrqSgzL
Further company coverage: ISR.ST
((terje.solsvik@thomsonreuters.com;))
Recent news on ISR Immune System Regulation Holding AB (publ)
See all newsBrief: ISR Holding Shares To Be Delisted From Nasdaq First North Growth Market
Brief: Nasdaq Stockholm Hands Over Investigation Of ISR Holding To Disciplinary Committee
Brief: ISR Immune System Regulation Holding Receives Notice Of Objection From Nasdaq
Brief: ISR FY 2022 Oper Loss Widens To SEK 205.1 Mln
Brief: ISR Signs Development Agreements With Catalent